Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GONAL-F RFF REDI-JECT vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Ovulation induction in anovulatory women,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART),Spermatogenesis induction in hypogonadotropic hypogonadism (with h CG)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
Terminal elimination half-life: approximately 24 hours; clinically, steady-state is achieved within 3-5 days of daily dosing.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Primarily metabolized in the liver via peptide hydrolysis, with renal excretion of metabolites.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Renal: approximately 70-80% of the dose; fecal: <20%
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Approximately 30-40% bound to plasma proteins, primarily albumin.
92% bound primarily to albumin
Approximately 8-10 L/kg, indicating extensive distribution into extracellular fluid.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous: approximately 70-80%.
Oral: 85% with high first-pass effect; IM: 100%
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or dialysis; use with caution.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated for use in pediatric patients. Safety and effectiveness not established.
Not approved for pediatric use.
Not indicated for use in geriatric patients. Safety and effectiveness not established.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
GONAL-F should only be used by physicians thoroughly familiar with infertility problems and their management. Use may lead to ovarian hyperstimulation syndrome (OHSS) and multiple gestations.
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian Hyperstimulation Syndrome (OHSS): risk of severe OHSS with pulmonary and vascular complications,Ovarian torsion and rupture,Multiple gestation and birth defects,Thromboembolic events,Ectopic pregnancy,Ovarian neoplasms,Respiratory distress syndrome in offspring
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to follitropin alfa or any excipient,High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., ovarian, breast, uterine),Pregnancy,Ovarian cyst or enlargement of unknown origin
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No known food interactions. No dietary restrictions required. However, grapefruit juice may increase estrogen levels and should be avoided during treatment. Maintain adequate hydration.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
FDA Pregnancy Category X. Contraindicated in pregnancy. No fetal risk data in first trimester due to lack of exposure; however, follicular stimulation may induce ovarian hyperstimulation syndrome and multiple gestations. Second and third trimester: no indicated use; potential for harm based on animal studies.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
Not recommended during breastfeeding. Excretion in human milk unknown; M/P ratio not determined. May suppress lactation due to hormonal effects.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
No dose adjustment; drug is contraindicated in pregnancy and should be discontinued if pregnancy occurs. No pharmacokinetic changes studied in pregnancy due to contraindication.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
GONAL-F RFF REDI-JECT contains recombinant human follicle-stimulating hormone (follitropin alfa). It is used for ovulation induction and controlled ovarian hyperstimulation. Administer subcutaneously, rotating injection sites. Monitor ovarian response via ultrasound and estradiol levels to avoid ovarian hyperstimulation syndrome (OHSS). Dose adjustments based on patient response; individualize therapy. Can be used in combination with Gn RH agonists or antagonists.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Rotate injection sites (abdomen, thigh, upper arm) to reduce lipodystrophy.,Do not shake the Redi-Ject device; store in refrigerator (2-8°C) before first use, then at room temperature for up to 28 days.,Report severe pelvic pain, nausea, or rapid weight gain (possible OHSS).,Avoid alcohol and grapefruit juice as they may affect hormone levels.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GONAL-F RFF REDI-JECT vs ANTAGONATE, answered by our medical review team.
GONAL-F RFF REDI-JECT is a Gonadotropin that works by GONAL-F (follitropin alfa) is a recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on ovarian follicles, stimulating follicular growth, maturation, and estrogen production.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GONAL-F RFF REDI-JECT and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GONAL-F RFF REDI-JECT is: Subcutaneous injection. Initial dose 75-225 IU once daily for 7-14 days, titrated based on ovarian response. Maximum daily dose 450 IU.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GONAL-F RFF REDI-JECT and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GONAL-F RFF REDI-JECT is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. No fetal risk data in first trimester due to lack of exposure; however, follicular stimulation may induce ovarian hyperstimu. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.